Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $90 to $101.
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $90 to $101.